Key result
The strategy of permissive cardiotoxicity proposes maintaining antitumor treatment without interruption when mild to moderate ventricular dysfunction is detected, provided cardiovascular risk is managed.
Highlights the clinical dilemma of managing cardiovascular toxicity during cancer treatment within the emerging field of cardio-oncology.
Cancer and cardiovascular diseases are the leading causes of mortality worldwide.As these diseases share common metabolic pathways, patients with cancer are currently seen as having subclinical alterations with great potential for developing cardiovascular diseases (and vice versa).This tenuous interrelationship has led to the emergence of cardiooncology (CO) as an area of study and discussion, with a major impact on the management of these cases.In clinical practice, CO is dominated by the dilemma of how to best manage cardiovascular toxicity during cancer Central Illustration: Permissive Cardiotoxicity: When the Optimal Is the Enemy of the Good Imagem Cardiovascular ABC
No takes yet. Share an insight, caveat, or question.
Silva et al. (2025) conducted a review in Cancer and chemotherapy-related cardiac dysfunction (CTRCD). Permissive cardiotoxicity strategy was evaluated. The strategy of permissive cardiotoxicity proposes maintaining antitumor treatment without interruption when mild to moderate ventricular dysfunction is detected, provided cardiovascular risk is managed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: